Chronic urticaria
MONDO:0850230An urticaria that is characterized by the presence of urticaria for a period exceeding 6 weeks, assuming symptoms for most days of the week.
20 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Can a diet tame chronic hives in teens?
Disease control Recruiting nowThis trial asks whether adding a Mediterranean diet or a low-histamine diet to standard care can reduce disease activity and improve quality of life in teens aged 12-18 with chronic spontaneous urticaria (CSU), a condition causing persistent hives. Participants are randomly assig…
Phase: NA • Sponsor: Saglik Bilimleri Universitesi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New shot may stop hives from cold and scratching
Disease control Recruiting nowThis study tests an investigational drug called barzolvolimab in 240 adults who get hives from cold temperatures or from scratching their skin, and whose symptoms are not controlled by standard allergy pills. Participants receive either the drug or a placebo injection, and doctor…
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New pill could tame stubborn hives
Disease control Recruiting nowThis study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Partic…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a histamine shot tame chronic hives?
Disease control Recruiting nowThis study looks at how well an injection called Immunoglobulin-Histamine complex (IHC, brand name Histoglob) works for people with chronic urticaria, or long-term hives. Researchers will track 600 patients in India to see if the treatment reduces hives and the need for other all…
Sponsor: Bharat Serums and Vaccines Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hives drug shows promise in early trial
Symptom relief Recruiting nowThis study tests a new medication called ARS-2 for people with chronic spontaneous urticaria (long-term hives). It aims to see if ARS-2 can quickly reduce itching and hives during flare-ups. The trial involves 42 adults who will receive either ARS-2 or a placebo during separate f…
Phase: PHASE2 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
Can a smartphone app ease the misery of eczema, psoriasis, and hives?
Symptom relief Recruiting nowThis study tests whether a mobile app that provides psychological tools can improve quality of life for people with eczema, psoriasis, or chronic hives. Participants use the app over 32 weeks to learn coping strategies and wellness tips. The goal is to see if this digital approac…
Phase: NA • Sponsor: National University Hospital, Singapore • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New drug aims to calm stubborn hives triggered by cold or scratching
Symptom relief Recruiting nowThis early-stage study tests a single dose of an experimental drug called GTX-B001 in healthy people and those with chronic inducible urticaria—a condition where cold or scratching causes painful hives. The main goal is to check safety and how the body handles the drug. About 72 …
Phase: PHASE1 • Sponsor: Granular Therapeutics Limited • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New pill for chronic hives enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage trial tests the safety of an experimental oral drug called EDP-978 in 98 healthy adults. Researchers will give single and multiple doses to see how the body handles it and whether it causes side effects. The drug is being developed for chronic hives, but this stu…
Phase: PHASE1 • Sponsor: Enanta Pharmaceuticals, Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC